Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 801 results for "gsk"

Imperial Group partnering with GSK to drive the growth of its South African brands

Imperial to support GlaxoSmithKline brands

Sales, merchandising and brand consulting services Leading global consumer healthcare group GlaxoSmithKline (GSK) has awarded a three-year contract for sales, merchandising and brand consulting services to Imperial Retail Solutions. This major ... Analytiqa, 9 hours ago
European Pharmaceutical Review

GSK begins dosing of patients in phase III study of sirukumab to treat giant cell arteritis

GSK announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA). GCA, a disease characterised by inflammation of ...
 PharmaBiz1 day ago GSK announces start of phase III study of sirukumab in Giant Cell Arteritis  Noodls3 days ago Phase III study of sirukumab in giant cell arteritis starts  European Pharmaceutical Review1 day ago GSK begins dosing in phase III study of sirukumab for treatment of giant cell arteritis  Pharmaceutical Business Review2 days ago

GSK wins 4 National Business Excellence Awards for 2nd ...

The GSK team with the four awards GlaxoSmithKline's (GSK's) Sri Lanka operations, encompassing pharmaceuticals and consumer nutritionals, won four National Business Excellence Awards (NBEAs) at the 2015 edition of the apex awards event of the ...
 Daily Mirror Sri Lanka1 day ago ABB Consulting receives prestigious national safety award  Scandinavian Oil-Gas Magazine3 days ago

GSK reboots in China

SHANGHAI: GlaxoSmithKline Plc (GSK) has cut 40% of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record US$490mil fine in 2014. The British ... days ago GSK Looks to Return to Growth in China  PharmaceuticalProcessing1 day ago The cost of cleaning up GSK's act in China  Reuters2 days ago GSK Launches Review of Ad Agency Roster  MarketingWorld1 day ago

GSK gets marketing authorisation in Europe for expanded indication of Volibris to treat PAH

The European Commission has approved a variation to expand the current therapeutic indication for GlaxoSmithKline's (GSK) Volibris (ambrisentan) to include its use in combination treatment for patients with pulmonary arterial hypertension (PAH). ...
 Pharmaceutical Technology3 days ago GLAXOSMITHKLINE : GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension  4 Traders4 days ago GSK receives European marketing authorisation to expand indication for Volibris in treatment of pulm  CPhI.cn3 days ago

Trivitron Healthcare founder GSK Velu to launch Rs 400 crore fund early 2016

A new fund of Rs 300 crore - Rs 400 crore focusing on healthcare and lifescience, spearheaded by Trivitron Healthcare founder G S K Velu is expected to hit the market by early next year. Velu, who recently sold his shares in pathology lab chain ...
 Smart Investor2 days ago
American Banking News

GlaxoSmithKline plc Given Market Perform Rating at Sanford C. Bernstein (GSK)

GlaxoSmithKline plc (LON:GSK)s stock had its market perform rating reaffirmed by investment analysts at Sanford C. Bernstein in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They currently have a GBX 1,399 ($21.16) ...
 American Banking News11 hours ago GlaxoSmithKline plc Receives Market Perform Rating from Sanford C. Bernstein (GSK)  American Banking News - Forex4 days ago Neutral rating GSK Consumer Healthcare: Slowing volume growth a concern  Financial Express6 days ago GlaxoSmithKline plc Receives Neutral Rating from JP Morgan Cazenove (GSK)  Ticker Report1 week ago
Contract Pharma

Idera, GSK to collaborate on renal disease

Home » Regions » Global News » Idera, GSK to collaborate on renal disease Wednesday, November 25, 2015 Idera Pharmaceuticals , a Cambridge, Mass.-based clinical-stage biopharmaceutical company developing toll-like receptors and RNA ...
 Center Watch3 days ago Idera, GSK to collaborate on third generation antisense molecules to treat renal disease  Pharmaceutical Business Review3 days ago Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease  Benzinga.com5 days ago Update: GSK inks $100 million deal with Idera Pharmaceuticals  Local Tech Wire4 days ago

BRIEF-Almirall buys rights to Veltin and Altabax from GSK's Stiefel

Nov 23 Almirall SA : * Buys rights to Veltin and Altabax from Stiefel, a GSK company, in exchange for distribution rights to Toctino * Veltin and Altabax will be commercialised through Aqua Pharmaceuticals, the company's US affiliate * ...
 Reuters5 days ago Almirall has acquired the rights to Veltin® and Altabax® from Stiefel, a GSK company, in exchange for its distribution rights to Toctino®  Noodls5 days ago Barcelona-based Almirall acquires rights to Veltin and Altabax from GSK's Stiefel  Pharmaceutical Tech.com4 days ago Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Company  DermWire5 days ago

Strides Shasun gets USFDA nod to sell copycats of GSK's Avodart

Strides wins approval from the US Food and Drug Administration to use dutasteride capsules in strengths of 0.5 milligram Strides Shasun was formed by the merger of Bengaluru-based Strides Arcolab and Shasun Pharmaceuticals last year. Bengaluru: ...
 Livemint.com1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gsk
Get updated on latest news & your favorite topics right in your inbox!
More     Less